Breaking News Instant updates and real-time market news.

CLVS

Clovis

$59.97

0.27 (0.45%)

, TSRO

Tesaro

$144.31

0.08 (0.06%)

08:07
06/19/17
06/19
08:07
06/19/17
08:07

Clovis should now be 'prime takeout candidate,' says Leerink

Leerink analyst Michael Schmidt views this morning's data from Clovis Oncology (CLVS) as the "best-case outcome." The data indicate that efficacy of the three leading PARP inhibitors look very comparable, Schmidt tells investors in a research note titled "Bull Case Plays Out as ARIEL3 Hits All Endpoints." Tesaro (TSRO) and AstraZeneca (AZN) own the other leading PARP inhibitors. The analyst expects shares of Clovis to "trade up significantly" on today's news. Clovis shares in premarket trading are up 40%, or $24.03, to $84.00. "With best-case data in hand," Clovis should be a "prime takeout candidate," Schmidt tells investors. He reiterates an Outperform rating on the shares.

CLVS

Clovis

$59.97

0.27 (0.45%)

TSRO

Tesaro

$144.31

0.08 (0.06%)

AZN

AstraZeneca

$34.54

0.43 (1.26%)

  • 26

    Jun

  • 30

    Jun

CLVS Clovis
$59.97

0.27 (0.45%)

06/16/17
FBCO
06/16/17
NO CHANGE
Target $88
FBCO
Outperform
Clovis price target raised to $88 from $74 at Credit Suisse
Credit Suisse analyst Alethia Young assumed coverage of Clovis Oncology (CLVS) and raised the firm's price target on the stock to $88 from $74, noting that her 2023 U.S. estimate for rucaparib is $1.3B versus prior coverage's forecast of $700M. Young, who thinks that the PARPi market is big enough that both Clovis and Tesaro (TSRO) can have blockbuster products, believes both companies are likely attractive targets for large global pharma companies, she tells investors. The analyst keeps an Outperform rating on Clovis shares.
06/01/17
RHCO
06/01/17
NO CHANGE
RHCO
SunTrust sees $240/share takeout price for Tesaro
After the Wall Street Journal reported yesterday that Tesaro (TSRO) is exploring a sale, albeit with "modest" interest, SunTrust analyst Peter Lawson says his analysis suggests a $240 per share takeout price for the company. Tesaro closed yesterday up $5.88, or 4%, to $149.31. Acquisitions in the PARP inhibitor space are more likely to happen after Clovis Oncology's (CLVS) ARIEL 3 data at the end of June, as the readout will provide a more apples-to-apples comparison to Tesaro and AstraZeneca (AZN), Lawson tells investors in a research note. His "bull case" points to a $286 per share price for Tesaro and $92 per share price for Clovis. Lawson has Buy ratings on both names. JPMorgan's Cory Kasimov this morning said he likes the setup for Clovis shares into the late June data announcement.
06/13/17
LEER
06/13/17
INITIATION
Target $85
LEER
Outperform
Clovis initiated with an Outperform at Leerink
Leerink analyst Michael Schmidt started Clovis Oncology with an Outperform rating and $85 price target. Rubraca, currently approved in the U.S. as a therapy in third line ovarian cancer patients, has "significant commercial potential" in other indications not currently adequately reflected in the stock's valuation, the analyst contends. Schmidt estimates Clovis shares could be worth $126 in a bull-case scenario, while the floor valuation of the stock is $33 in a worst-case scenario if ARIL3 outright fails. He also sees the company as a "compelling" takeover target.
06/13/17
06/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Clovis (CLVS) initiated with an Outperform at Leerink. 2. Arconic (ARNC) resumed with an Equal Weight at Morgan Stanley. 3. Tesoro (TSO) reinstated with a Conviction Buy at Goldman Sachs. 4. Golden Ocean (GOGL) initiated with a Buy at Seaport Global. 5. International Seaways (INSW) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TSRO Tesaro
$144.31

0.08 (0.06%)

06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Tesaro prostate study suspension due to fast enrollment, says Credit Suisse
After speaking to Tesaro (TSRO), after they spoke to their partner Johnson & Johnson (JNJ), Credit Suisse analyst Alethia Young said the news of the companies' suspension of participant recruitment in the study of niraparib in prostate cancer is actually positive, since it is due to the trial enrolling faster than expected. The suspension has nothing to do with safety or efficacy and is not a clinical hold, but is due to having too many patients in the first part of trial, Young was told. She maintains an Outperform rating on Tesaro shares.
06/09/17
06/09/17
NO CHANGE

Tesaro tells Janney 'no clinical hold, no suspension' in prostate cancer study
After Tesaro (TSRO) shares saw weakness earlier associated with a notice indicating that enrollment was halted in its Johnson & Johnson (JNJ) partnered prostate cancer study, the company told Janney Capital analyst Debjit Chattopadhyay that there is "no clinical hold, no suspension, no safety issues, nothing going on. The first cohort enrolled quickly and we need to see data before starting to enroll the next group - standard trial conduct... JNJ's screening pool was large due to interest, and screen failure rate was lower than expected. Hence, JNJ stopped screening or they would be at risk of enrolling the whole trial before they get to the first data from run in." The analyst, who expect Tesaro shares to be range bound until peer data and regulatory events, keeps a Neutral rating on the stock, which has recovered all of its earlier losses and is now about flat for the session.
06/12/17
RHCO
06/12/17
NO CHANGE
RHCO
Misunderstanding creates buying opportunity in Tesaro stock, says SunTrust
SunTrust analyst Peter Lawson says that the suspension of participant recruitment by Johnson & Johnson (JNJ) for a study of Tesaro's (TSRO) PARP inhibitor Zejula in prostate cancer "is being incorrectly viewed as a clinical hold." After speaking with J&J, Lawson says that the suspension was not due to clinical or safety issues, but to overly fast enrollment. The analyst says that the early data on PARP inhibitors in prostate cancer has been "encouraging." He believes that the misunderstanding has created a buying opportunity in Tesaro stock. .
AZN AstraZeneca
$34.54

0.43 (1.26%)

06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/05/17
PIPR
06/05/17
NO CHANGE
PIPR
Piper views AstraZeneca, J&J as ASCO standouts
The standouts at ASCO over the weekend were the "compelling results" presented on Johnson & Johnson's (JNJ) Zytiga from the Latitude study in prostate cancer and AstraZeneca's (AZN) Lynparza in the OlympiAD trial in BRCA mutant breast cancer, Piper Jaffray analyst Richard Purkiss tells investors in a research note. In lung cancer, Merck's (MRK) updated data in KN021G "appears more promising" than Bristol-Myers' (BMY) updated data in CM012, the analyst adds. Purkiss believes, however, that relative to recent ASCOs, the data "so far in totality is underwhelming."
05/17/17
JPMS
05/17/17
UPGRADE
Target $72
JPMS
Overweight
Clovis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib.

TODAY'S FREE FLY STORIES

RAD

Rite Aid

$3.93

0.19 (5.08%)

, WBA

Walgreens Boots Alliance

$77.09

-0.17 (-0.22%)

20:25
06/28/17
06/28
20:25
06/28/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

RAD

Rite Aid

$3.93

0.19 (5.08%)

WBA

Walgreens Boots Alliance

$77.09

-0.17 (-0.22%)

MKC

McCormick

$98.95

0.42 (0.43%)

LNN

Lindsay

$88.04

1.44 (1.66%)

GBX

Greenbrier

$50.00

0.55 (1.11%)

CAG

Conagra Brands

$37.37

0.37 (1.00%)

STZ

Constellation Brands

$183.68

1.4 (0.77%)

AYI

Acuity Brands

$179.73

4.4 (2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 07

    Jul

FUL

H.B. Fuller

$53.67

1.59 (3.05%)

19:53
06/28/17
06/28
19:53
06/28/17
19:53
Earnings
H.B. Fuller narrows FY17 adjusted EPS to $2.57-$2.67 from $2.57-$2.77 »

EPS consensus $2.66.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

FUL

H.B. Fuller

$53.67

1.59 (3.05%)

19:51
06/28/17
06/28
19:51
06/28/17
19:51
Earnings
H.B. Fuller reports Q2 adjusted EPS 62c, consensus 67c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

NERV

Minerva

$7.95

-0.65 (-7.56%)

19:46
06/28/17
06/28
19:46
06/28/17
19:46
Syndicate
Minerva 5M share Secondary priced at $7.75 »

Citi and Jefferies acted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

GOV

Government Properties

$19.33

-2.565 (-11.72%)

19:45
06/28/17
06/28
19:45
06/28/17
19:45
Syndicate
Government Properties 25M share Secondary priced at $18.50 »

Citi, BofA/Merrill,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

APRN

Blue Apron

19:41
06/28/17
06/28
19:41
06/28/17
19:41
Syndicate
Blue Apron 30M share IPO priced at $10.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

SO

Southern Company

$49.15

-0.25 (-0.51%)

, TOSBF

Toshiba, also use TOSYY

$2.57

-0.03 (-1.15%)

19:29
06/28/17
06/28
19:29
06/28/17
19:29
Hot Stocks
Georgia Power, Southern Nuclear to assume Vogtle project management by late July »

Georgia Power (SO) and…

SO

Southern Company

$49.15

-0.25 (-0.51%)

TOSBF

Toshiba, also use TOSYY

$2.57

-0.03 (-1.15%)

TOSYY

Toshiba, also use TOSBF

$15.28

-0.39 (-2.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$199.62

0.73 (0.37%)

, BDRBF

Bombardier

$1.87

0.039 (2.13%)

19:29
06/28/17
06/28
19:29
06/28/17
19:29
Periodicals
Boeing requests delay in ruling on Bombardier complaint, Reuters says »

Boeing (BA) has requested…

BA

Boeing

$199.62

0.73 (0.37%)

BDRBF

Bombardier

$1.87

0.039 (2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BAC

Bank of America

$23.88

0.61 (2.62%)

, BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

19:22
06/28/17
06/28
19:22
06/28/17
19:22
Periodicals
Berkshire may swap Bank of America preferred shares after CCAR news, WSJ says »

After Bank of America…

BAC

Bank of America

$23.88

0.61 (2.62%)

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WATT

Energous

$15.39

0.16 (1.05%)

, DLGNF

Dialog Semiconductor

19:01
06/28/17
06/28
19:01
06/28/17
19:01
Hot Stocks
Dialog invests extra $15M in Energous »

Energous (WATT) announced…

WATT

Energous

$15.39

0.16 (1.05%)

DLGNF

Dialog Semiconductor

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$187.92

0.51 (0.27%)

18:59
06/28/17
06/28
18:59
06/28/17
18:59
Periodicals
Anthem to curtail plan offerings in most of Nevada, WSJ reports »

Anthem plans to stop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSN

VeriSign

$93.77

0.97 (1.05%)

18:36
06/28/17
06/28
18:36
06/28/17
18:36
Hot Stocks
VeriSign says renews .net control through 2023 »

VeriSign disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DD

DuPont

$81.28

0.59 (0.73%)

, DOW

Dow Chemical

$63.25

0.62 (0.99%)

18:34
06/28/17
06/28
18:34
06/28/17
18:34
Hot Stocks
DuPont, Dow Chemical boards reiterate support of merger agreement »

Dow Chemical Company…

DD

DuPont

$81.28

0.59 (0.73%)

DOW

Dow Chemical

$63.25

0.62 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TPX

Tempur Sealy

$50.87

0.07 (0.14%)

18:33
06/28/17
06/28
18:33
06/28/17
18:33
Hot Stocks
Tempur Sealy enters standstill pact with H Partners, board member Nabi »

Tempur Sealy disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALJ

Alon USA Energy

$13.33

0.15 (1.14%)

, DK

Delek US

$26.43

0.25 (0.95%)

18:26
06/28/17
06/28
18:26
06/28/17
18:26
Hot Stocks
Alon USA Energy stockholders approve Delek US merger »

Alon USA Energy (ALJ)…

ALJ

Alon USA Energy

$13.33

0.15 (1.14%)

DK

Delek US

$26.43

0.25 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

ANCUF

Alimentation Couche-Tard

$49.30

0.144 (0.29%)

, CST

CST Brands

18:25
06/28/17
06/28
18:25
06/28/17
18:25
Hot Stocks
Alimentation Couche-Tard confirms closing of CST Brands acquisition »

Alimentation Couche-Tard…

ANCUF

Alimentation Couche-Tard

$49.30

0.144 (0.29%)

CST

CST Brands

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$50.60

0.92 (1.85%)

18:04
06/28/17
06/28
18:04
06/28/17
18:04
Hot Stocks
BNY Mellon announces strategic alliance with One Investment Group »

BNY Mellon and One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

PRGS

Progress Software

$30.82

0.74 (2.46%)

, WOR

Worthington

$47.36

2 (4.41%)

18:03
06/28/17
06/28
18:03
06/28/17
18:03
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

PRGS

Progress Software

$30.82

0.74 (2.46%)

WOR

Worthington

$47.36

2 (4.41%)

GEMP

Gemphire Therapeutics

$12.27

0.43 (3.63%)

NXTD

Nxt-ID

$1.66

0.2505 (17.77%)

KLIC

Kulicke & Soffa

$20.02

0.53 (2.72%)

SRPT

Sarepta

$33.86

0.83 (2.51%)

SPLS

Staples

$9.93

0.77 (8.41%)

FITB

Fifth Third

$25.49

0.4 (1.59%)

DFS

Discover

$61.88

0.81 (1.33%)

STI

SunTrust

$56.09

0.88 (1.59%)

C

Citi

$65.18

0.95 (1.48%)

RF

Regions Financial

$14.09

0.09 (0.64%)

BK

BNY Mellon

$50.60

0.92 (1.85%)

JPM

JPMorgan

$89.82

1.77 (2.01%)

CFG

Citizens Financial

$35.34

0.5 (1.44%)

BAC

Bank of America

$23.88

0.61 (2.62%)

MS

Morgan Stanley

$44.32

0.1 (0.23%)

WFC

Wells Fargo

$54.33

1.17 (2.20%)

PNC

PNC Financial

$123.40

2.28 (1.88%)

ZION

Zions Bancorp

$42.97

0.43 (1.01%)

GS

Goldman Sachs

$223.22

2.94 (1.33%)

AXP

American Express

$83.97

0.89 (1.07%)

USB

U.S. Bancorp

$51.98

0.84 (1.64%)

PIR

Pier 1 Imports

$5.38

0.04 (0.75%)

BLCM

Bellicum Pharmaceuticals

$13.32

0.18 (1.37%)

AKBA

Akebia

$15.50

-0.19 (-1.21%)

DOC

Physicians Realty Trust

$21.60

0.08 (0.37%)

CRZO

Carrizo Oil & Gas

$15.61

-0.47 (-2.92%)

COF

Capital One

$82.98

1.6 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 14

    Jul

  • 14

    Jul

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 21

    Jul

  • 25

    Jul

  • 26

    Jul

  • 03

    Aug

  • 26

    Sep

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 30

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

VRX

Valeant

$17.15

0.5 (3.00%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Salix confirms FDA accepts NDA for PLENVU »

Valeant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

NTNX

Nutanix

$20.36

1.72 (9.23%)

, GOOG

Alphabet

$940.49

13.16 (1.42%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Nutanix announces strategic alliance with Google Cloud »

Nutanix (NTNX) announced…

NTNX

Nutanix

$20.36

1.72 (9.23%)

GOOG

Alphabet

$940.49

13.16 (1.42%)

GOOGL

Alphabet Class A

$961.01

12.92 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

CE

Celanese

$93.42

0.62 (0.67%)

18:02
06/28/17
06/28
18:02
06/28/17
18:02
Hot Stocks
Celanese increases price of Dibutyl Maleate and Dioctyl Maleate in Europe »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$223.22

2.94 (1.33%)

18:00
06/28/17
06/28
18:00
06/28/17
18:00
Hot Stocks
Goldman Sachs: Fed did not object to capital plan »

Goldman Sachs announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 17

    Oct

COLB

Columbia Banking

$39.35

0.49 (1.26%)

17:56
06/28/17
06/28
17:56
06/28/17
17:56
Hot Stocks
Columbia Banking names Hadley Robbins CEO »

Columbia Banking System…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFBK

Northfield Bancorp

$17.36

0.3 (1.76%)

17:55
06/28/17
06/28
17:55
06/28/17
17:55
Hot Stocks
Northfield Bancorp CEO John Alexander to retire, Steven Klein to succeed »

Northfield Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$22.96

0.25 (1.10%)

, AAL

American Airlines

$49.25

0.75 (1.55%)

17:43
06/28/17
06/28
17:43
06/28/17
17:43
Hot Stocks
Homeland Security announces new aviation security measures »

Secretary of Homeland…

JBLU

JetBlue

$22.96

0.25 (1.10%)

AAL

American Airlines

$49.25

0.75 (1.55%)

UAL

United Continental

$76.70

0.7 (0.92%)

DAL

Delta Air Lines

$53.84

1 (1.89%)

LUV

Southwest

$62.01

0.5 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 07

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.